Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer

Lu,Weipeng; Wei,Hong; Li,Mei; Wang,Hai; Liu,Lina; Zhang,Qiuping; Liu,Lisha; Lu,Shen

doi:10.3892/mmr.2015.3530

Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer

Authors:
- Weipeng Lu
- Hong Wei
- Mei Li
- Hai Wang
- Lina Liu
- Qiuping Zhang
- Lisha Liu
- Shen Lu
View Affiliations

Affiliations: Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R. China, Department of Pathology, The Third People's Hospital of Dalian, Dalian, Liaoning 116000, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R. China, Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, P.R. China
Published online on: March 23, 2015 https://doi.org/10.3892/mmr.2015.3530
Pages: 1219-1224

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth factor receptor, is currently considered to be the strategy with the most potential for the treatment of gastric cancer due to the low frequency of KRAS mutations in patients with gastric cancer. However, the therapeutic success of cetuximab in colorectal cancer (CRC) has demonstrated that the clinical effect of cetuximab is closely dependent not only on KRAS mutations, but also BRAF and phosphoinositide‑3‑kinase, catalytic, α polypeptide (PIK3CA) mutations. In the present study, the status of KRAS, BRAF and PIK3CA mutations in gastric cancer were investigated concomitantly in order to aid the selection of patients eligible for treatment with cetuximab. Mutations in KRAS (exon 2), BRAF (exon 15) and PIK3CA (exon 9 and exon 20) were retrospectively evaluated by high resolution melting analysis and DNA direct sequencing in samples from 156 patients with gastric cancer. Mutations in either KRAS or PIK3CA were identified in 13 samples (8.3%), 7 samples with KRAS mutations and 6 samples with PIK3CA mutations. No mutations in the BRAF gene were identified. The frequency of mutations in either KRAS or PIK3CA were significantly higher in patients without lymph node metastasis than those with. Furthermore, KRAS and PIK3CA mutations were mutually exclusive. The present study, therefore, suggested that it may be necessary to evaluate KRAS and PIK3CA mutations concomitantly for the selection of patients eligible for treatment with cetuximab.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Janunger KG, Hafström L, Nygren P and Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 40:309–326. 2001. View Article : Google Scholar : PubMed/NCBI
3	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
4	Rojo F, Tabernero J, Albanell J, et al: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol. 24:4309–4316. 2006. View Article : Google Scholar : PubMed/NCBI
5	Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R and Suriano G: Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer. 8:102008. View Article : Google Scholar : PubMed/NCBI
6	Liu Z, Liu L, Li M, et al: Epidermal growth factor receptor mutation in gastric cancer. Pathology. 43:234–238. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
8	Rivera F, Vega-Villegas ME and López-Brea MF: Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 19:99–113. 2008. View Article : Google Scholar : PubMed/NCBI
9	Chan JA, Blaszkowsky LS, Enzinger PC, et al: A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 22:1367–1373. 2011. View Article : Google Scholar : PubMed/NCBI
10	Schoennemann KR, Bjerregaard JK, Hansen TP, et al: Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 14:219–225. 2011. View Article : Google Scholar : PubMed/NCBI
11	Shi M, Ji J, Wu J, et al: Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution. Hepatogastroenterology. 59:1054–1058. 2012.PubMed/NCBI
12	Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
13	De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
14	Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 4:e72872009. View Article : Google Scholar : PubMed/NCBI
15	Victor T, Du Toit R, Jordaan AM, Bester AJ and van Helden PD: No evidence for point mutations in codons 12, 13 and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res. 50:4911–4914. 1990.PubMed/NCBI
16	Hongyo T, Buzard GS, Palli D, et al: Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 55:2665–2672. 1995.PubMed/NCBI
17	Liu ZM, Liu LN, Li M, Zhang QP, Cheng SH and Lu S: Mutation detection of KRAS by high-resolution melting analysis in Chinese gastric cancer. Oncol Rep. 22:515–520. 2009.PubMed/NCBI
18	Corso G, Velho S, Paredes J, et al: Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 47:443–451. 2011. View Article : Google Scholar
19	Lee SH, Lee JW, Soung YH, et al: BRAF and KRAS mutations in stomach cancer. Oncogene. 22:6942–6945. 2003. View Article : Google Scholar : PubMed/NCBI
20	Kim IJ, Park JH, Kang HC, et al: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet. 114:118–120. 2003. View Article : Google Scholar : PubMed/NCBI
21	Oliveira C, Pinto M, Duval A, et al: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 22:9192–9196. 2003. View Article : Google Scholar : PubMed/NCBI
22	Wu M, Semba S, Oue N, Ikehara N, Yasui W and Yokozaki H: BRAF/K-ras mutation, microsatellite instability and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. Gastric Cancer. 7:246–253. 2004. View Article : Google Scholar
23	Zhao W, Chan TL, Chu KM, Chan AS, Stratton MR, Yuen ST and Leung SY: Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer. 108:167–169. 2004. View Article : Google Scholar
24	Sasao S, Hiyama T, Tanaka S, Yoshihara M, Yasui W and Chayama K: Clinicopathologic and genetic characteristics of gastric cancer in young male and female patients. Oncol Rep. 16:11–15. 2006.PubMed/NCBI
25	Stella G, Rojas Llimpe F, Barone C, et al: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. ASCO Meet Abstr. 27:e155032009.
26	Li VS, Wong CW, Chan TL, et al: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005. View Article : Google Scholar : PubMed/NCBI
27	Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
28	Velho S, Oliveira C, Ferreira A, et al: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 41:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
29	Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
30	Kiaris H and Spandidos D: Mutations of ras genes in human tumors (review). Int J Oncol. 7:413–421. 1995.PubMed/NCBI
31	van Grieken NC, Aoyama T, Chambers PA, et al: KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. Br J Cancer. 108:1495–1501. 2013. View Article : Google Scholar : PubMed/NCBI
32	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
33	Lee SH, Ahn BK, Baek SU and Chang HK: BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer. Gastroenterol Rep (Oxf). 1:70–74. 2013. View Article : Google Scholar
34	Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T and Grigsby PW: BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer. 61:1168–1172. 2014. View Article : Google Scholar : PubMed/NCBI
35	Campbell IG, Russell SE, Choong DY, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
36	Lee JW, Soung YH, Kim SY, et al: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar
37	Simi L, Pratesi N, Vignoli M, et al: High-resolution melting analysis for rapid detection of KRAS, BRAF and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 130:247–253. 2008. View Article : Google Scholar : PubMed/NCBI